TITLE

Haemorrhagic cystitis in haematopoietic stem cell transplantation (HSCT): a prospective observational study of incidence and management in HSCT centres within the GITMO network (Gruppo Italiano Trapianto Midollo Osseo)

AUTHOR(S)
Gargiulo, G.; Orlando, L.; Alberani, F.; Crabu, G.; Di Maio, A.; Duranti, L.; Errico, A.; Liptrott, S.; Pitrone, R.; Santarone, S.; Soliman, C.; Trunfio, A.; Selleri, C.; Bruno, B.; Mammoliti, S.; Pane, F.
PUB. DATE
June 2014
SOURCE
Ecancermedicalscience;2014, Vol. 8 Issue 413-446, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Haemorrhagic cystitis (HC) is a recognised complication in patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT). This study evaluates the incidence and severity of HC in patients undergoing allogeneic HSCT during hospitalisation and within the first 100 days following transplant, looking at the use of prophylaxis, management of HC, outcomes at 100 days post transplant, and to identify any correlations between development of HC and the different conditioning regimens for transplant or HC prevention methods used. Results: Four hundred and fifty patients (412 adult and 38 paediatric) were enrolled in this prospective, multicentre, and observational study. HC was observed in 55 patients (12.2%) of which 8/38 were paediatric (21% of total paediatric sample) and 47/412 adults (11.4% of total adult sample). HC was observed primarily in the non-related HSCT group (45/55; 81.8%, p = 0.001) compared to sibling and myeloablative transplant protocols (48/55; 87.3%; p = 0.008) and with respect to reduced intensity conditioning regimens (7/55;12.7%). In 33 patients with HC (60%), BK virus was isolated in urine samples, a potential co-factor in the pathogenesis of HC. The median day of HC presentation was 23 days post HSCT infusion, with a mean duration of 20 days. The most frequent therapeutic treatments were placement of a bladder catheter (31/55; 56%) and continuous bladder irrigation (40/55; 73%). The range of variables in terms of conditioning regimens and so on, makes analysis difficult. Conclusions: This multi-centre national study reported similar incidence rates of HC to those in the literature. Evidence-based guidelines for prophylaxis and management are required in transplant centres. Further research is required to look at both prophylactic and therapeutic interventions, which also consider toxicity of newer conditioning regimens.
ACCESSION #
97255396

 

Related Articles

  • Effect of the order of TBI and cyclophosphamide administration on the outcome of allogeneic hematopoietic stem cell transplantation. Motohashi, K; Fujisawa, S; Onizuka, M; Kako, S; Sakaida, E; Shono, K; Tatara, R; Doki, N; Mori, T; Sakura, T; Aotsuka, N; Fuji, E; Tomita, N; Kawai, N; Saitoh, T; Usuki, K; Taguchi, J; Watanabe, R; Kobayashi, S; Yano, S // Bone Marrow Transplantation;Nov2015, Vol. 50 Issue 11, p1476 

    The article analyses the effect of the order of total body irradiation (TBI) and cyclophosphamide administration on the outcome of allogeneic hematopoietic stem cell transplantation. Topics discussed include retrospective study to analyse the transplant outcomes of patients with acute myeloid...

  • Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings. Tischer, Johanna; Engel, Nicole; Fritsch, Susanne; Prevalsek, Dusan; Hubmann, Max; Schulz, Christoph; Zoellner, Anna-K.; Bücklein, Veit; Reibke, Roland; Mumm, Friederike; Rieger, Christina; Hill, Wolfgang; Ledderose, Georg; Stemmler, Hans; Köhnke, Thomas; Jäger, Gundula; Kolb, Hans; Schmid, Christoph; Moosmann, Andreas; Hausmann, Andreas // Annals of Hematology;Oct2015, Vol. 94 Issue 10, p1677 

    We retrospectively compared the incidence of virus infections and outcome in the context of immune reconstitution in two different HLA-haploidentical transplantation (haplo-HSCT) settings. The first was a combined T-cell-replete and T-cell-deplete approach using antithymocyte globulin (ATG)...

  • Association of Busulfan and Cyclophosphamide Conditioning with Sleep Disorders after Hematopoietic Stem Cell Transplantation. Faulhaber, Gustavo A. M.; Furlanetto, Tania W.; Astigarraga, Claudia C.; Filho, Humberto Luiz Moser; Paludo, Angela Paula; Silla, Lucia M. R. // Acta Haematologica;Oct2010, Vol. 124 Issue 2, p125 

    New indications and conditioning regimens for hematopoietic stem cell transplantation (HSCT) have emerged in the last 10 years. Previous studies have shown the association of HSCT with late effects such as sleep disorders. The aim of this study was to determine the prevalence and factors...

  • Pharmacogenetics of Gemtuzumab-Associated Hepatic Sinusoidal Occlusion Syndrome after Hematopoietic Stem Cell Transplant. Aplenc, Richard; Vachani, Anil; Han, Peggy; Glatfelter, Wendy; Sievers, Eric L. // Acta Haematologica;Dec2003, Vol. 110 Issue 4, p207 

    Presents a study that investigated the pharmacogenetics of Gemtuzumab-associated hepatic sinusoidal occlusion syndrome (SOS) after hematopoietic stem cell transplant (HSCT). Variable risk of SOS development in patients exposed to gemtuzumab after HSCT; Analysis of reactive oxygen species...

  • Late-onset hemorrhagic cystitis after hematopoietic stem cell transplantation in children. Kondo, M; Kojima, S; Kato, K; Matsuyama, T // Bone Marrow Transplantation;11/15/98, Vol. 22 Issue 10, p995 

    We analyzed the incidence, complications, and risk factors for late-onset hemorrhagic cystitis (HC) in 256 children undergoing hematopoietic stem cell transplantation (HSCT). Twenty-six recipients (10.2%) developed late-onset HC between 3 and 270 days (median, 33 days) after HSCT. In most...

  • A modified busulfan and cyclophosphamide preparative regimen for allogeneic transplantation in myeloid malignancies. Cai, Xiaojin; Wei, Jialing; He, Yi; Yang, Dongling; Jiang, Erlie; Huang, Yong; Han, Mingzhe; Feng, Sizhou // International Journal of Clinical Pharmacy;Feb2015, Vol. 37 Issue 1, p44 

    Background Busulfan/cyclophosphamide (Bu/Cy) is commonly used as a standard conditioning regimen without total body irradiation for patients with hematological myeloid malignancies undergoing hematopoietic stem cell transplantation (HSCT). Objective To develop a new myeloablative conditioning...

  • HY Immune Tolerance Is Common in Women without Male Offspring. Dierselhuis, Miranda P.; Jankowska-Gan, Ewa; Blokland, Els; Pool, Jos; Burlingham, William J.; van Halteren, Astrid G. S.; Goulmy, Els // PLoS ONE;Mar2014, Vol. 9 Issue 3, p1 

    Background: Sex difference is an established risk factor for hematopoietic stem cell transplantation (HSCT)-related complications like graft versus host disease (GVHD). CD8pos cytotoxic T cells specific for Y chromosome-encoded minor Histocompatibility antigens (HY) play an important role...

  • Antiviral agent reduced cytomegalovirus disease after HSCT.  // Hem/Onc Today;10/25/2013, Vol. 14 Issue 20, p46 

    The article presents the results of a randomized study as of late October 2013, which showed that patients who underwent hematopoietic stem cell transplantation were less likely to contract cytomegalovirus diseases when treated with higher doses of the antiviral agent brincidofovir.

  • Allogeneic HSCT improved outcomes for children with relapsed ALL.  // Hem/Onc Today;8/10/2013, Vol. 14 Issue 15, p20 

    The article discusses research in Germany on the benefit of allogeneic hematopoietic stem cell transplantation (HSCT) in improving the prognosis of patients with acute lymphoblastic leukemia (ALL), referencing a study by C. Eckert published in an issue of the "Journal of Clinical Oncology."

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics